ZYMEWORKS INC. COMMON STOCK

NASDAQ: ZYME (Zymeworks Inc.)

Last update: 2 days ago, 2:30PM

12.50

-0.06 (-0.44%)

Previous Close 12.55
Open 12.45
Volume 230,689
Avg. Volume (3M) 590,534
Market Cap 935,181,952
Price / Sales 10.38
Price / Book 2.75
52 Weeks Range
8.32 (-33%) — 17.70 (41%)
Earnings Date 30 Jul 2025 - 4 Aug 2025
Profit Margin -121.73%
Operating Margin (TTM) -94.48%
Diluted EPS (TTM) -1.50
Quarterly Revenue Growth (YOY) 170.30%
Total Debt/Equity (MRQ) 5.68%
Current Ratio (MRQ) 4.71
Operating Cash Flow (TTM) -75.78 M
Levered Free Cash Flow (TTM) -21.20 M
Return on Assets (TTM) -13.89%
Return on Equity (TTM) -29.80%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Zymeworks Inc. Bearish Bearish

AIStockmoo Score

-0.3
Analyst Consensus -2.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators 0.5
Average -0.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ZYME 935 M - - 2.75
CRNX 3 B - - 2.12
IRON 2 B - - 2.68
HRMY 2 B - 12.16 2.56
NVAX 1 B - 2.47 -
CDTX 1 B - - 7.20

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 0.19%
% Held by Institutions 103.29%

Ownership

Name Date Shares Held
Redmile Group, Llc 31 Mar 2025 4,788,945
Bnp Paribas Asset Management Holding S.A. 31 Mar 2025 2,197,879
52 Weeks Range
8.32 (-33%) — 17.70 (41%)
Median 13.00 (4.04%)
Total 1 Hold
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 03 Jul 2025 13.00 (4.04%) Hold 12.50

No data within this time range.

Date Type Details
30 May 2025 Announcement Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
30 May 2025 Announcement Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
22 May 2025 Announcement Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
22 May 2025 Announcement Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
21 May 2025 Announcement Zymeworks Announces Participation in Upcoming Investor Conferences
21 May 2025 Announcement Zymeworks Announces Participation in Upcoming Investor Conferences
19 May 2025 Announcement Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
19 May 2025 Announcement Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
14 May 2025 Announcement Three Finalists Announced for the 2025 Bloom Burton Award
25 Apr 2025 Announcement Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
25 Apr 2025 Announcement Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
21 Apr 2025 Announcement Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
21 Apr 2025 Announcement Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
17 Apr 2025 Announcement Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria